TICKERNERD
Menu
ZVRAZVRAHealthcare · Biotechnology

ZVRA Stock Forecast: Zevra Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$12
−0.41% on the day

The 9 Wall Street analysts covering Zevra Therapeutics, Inc. hold a median 12-month price target of $24 — +99.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 10 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$715.0M
Ticker Nerd rank
98 / 100
Median analyst target
$24
Analysts covering
9
Revenue$39.7M+53.3% y/y
Operating income$16.8M
Net income$8.8M
Free cash flow$16.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.2%
1M
+5.9%
YTD
+34.0%
1Y
+51.1%
From 52W high
−18.6%
From 52W low
+66.1%
$7
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ZVRA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Zevra Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
98 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Value
98
Growth
92
Volatility
89
Revisions
86
Issuance
73
Momentum
56
Size
49
Accruals
25

Quality (99): The business earns solid, repeatable profits on what it owns.

Accruals (25): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ZVRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZVRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26ZVRAHigh $35Median $24Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $20Median $24High $35

The green dot is the last close — the median target sits +99.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
20 Aug 2026HC Wainwright & Co.ReiteratesBuy$26
7 Aug 2026GuggenheimMaintainsBuy—
7 Aug 2026GuggenheimMaintainsBuy$24 → $23
6 Aug 2026CitizensMaintainsMarket Outperform—
6 Aug 2026CitizensMaintainsMarket Outperform$25 → $28
27 July 2026BTIGMaintainsBuy$27 → $24
27 July 2026BTIGMaintainsBuy—
27 July 2026Canaccord GenuityMaintainsBuy$29 → $20
27 July 2026Canaccord GenuityMaintainsBuy—
27 July 2026GuggenheimMaintainsBuy—
27 July 2026GuggenheimMaintainsBuy$29 → $24
23 June 2026HC Wainwright & Co.ReiteratesBuy$26
23 June 2026HC Wainwright & Co.ReiteratesBuy—
11 June 2026Canaccord GenuityMaintainsBuy—
10 June 2026GuggenheimMaintainsBuy—
10 June 2026Maxim GroupMaintainsBuy—
9 June 2026BTIGReiteratesBuy—
9 June 2026Canaccord GenuityMaintainsBuy—
9 June 2026CitizensMaintainsMarket Outperform—
8 June 2026Cantor FitzgeraldMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZVRA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ZVRA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Zevra Therapeutics, Inc. returned +51.1% against +17.5% for the S&P 500, dividends included.

ZVRA vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200Oct 25Jan 26Apr 26Jul 26ZVRAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ZVRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−2.0%
Analysts raising
1
Analysts cutting
0
Fundamentals

Zevra Therapeutics, Inc. (ZVRA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
13.7×

Cheaper than 49% of US stocks

Price / sales
5.3×

Cheaper than 24% of US stocks

Price / book
3.3×

Cheaper than 30% of US stocks

EV / EBITDA
12.2×

Cheaper than 30% of US stocks

Growth & margins
Revenue growth (YoY)
53.3%

Higher than 87% of US stocks

Earnings growth (YoY)
−88.3%

Higher than 4% of US stocks

Gross margin
96.2%

Higher than 98% of US stocks

Operating margin
42.3%

Higher than 93% of US stocks

Net margin
42.8%

Higher than 95% of US stocks

Returns & dividend
Return on equity
34.8%

Higher than 90% of US stocks

Return on assets
8.7%

Higher than 90% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Zevra Therapeutics, Inc. (ZVRA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Zevra Therapeutics, Inc. has a market value of $715.0M and an enterprise value of $494.9M.

  • Revenue in the twelve months to 30 June 2026: $136.1M. The latest quarter grew 53.3% year on year.

  • Net income over the same four quarters: $58.3M, a 42.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: $32.6M.

  • Shares outstanding: 59.3M.

  • Trailing P/E: 13.7×; forward P/E: 11.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Zevra Therapeutics, Inc. employs 61 people — $2.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 10 Sept 2026

Data provided by Twelve Data

Peers

ZVRA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ZVRAZevra Therapeutics, Inc.$715.0M
98
NVCTNuvectis Pharma, Inc.$709.0M
67
NGNENeurogene, Inc.$697.2M
60
CBIOCrescent Biopharma, Inc.$719.2M
57
AURAAura Biosciences, Inc.$722.7M
41
CTMXCytomX Therapeutics, Inc.$724.2M
47
MPLTMapLight Therapeutics, Inc.$728.5M
12

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Zevra Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ZVRA news & analysis

Zevra Therapeutics to Present at Upcoming Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

Zevra Therapeutics announced that members of its executive leadership team will present at upcoming investor conferences in New York, NY. The company is a commercial-stage firm focused on therapeutics for people living with rare diseases.

Why it matters — The presentations offer investors and analysts an opportunity to hear directly from Zevra's executive leadership about the company at upcoming investor conferences.

Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

GlobeNewsWire · 25 Aug 2026positive

Zevra Therapeutics announced it will present two posters featuring long-term real-world data on MIPLYFFA (arimoclomol) for the treatment of Niemann-Pick disease type C at the 2026 SSIEM Annual Symposium. The presentations are described as expanding the body of evidence supporting the long-term safety and effectiveness of arimoclomol in NPC.

Why it matters — ZVRA watchers would care because new real-world evidence on MIPLYFFA supports the drug's long-term safety and effectiveness profile in Niemann-Pick disease type C.

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 21 Aug 2026neutral

Zevra Therapeutics granted options to purchase an aggregate of 92,200 shares of common stock to four new employees under its 2023 Employment Inducement Award Plan. The awards vest over four years, with 25% vesting on the first anniversary of each employee's start date and the remainder in three equal annual installments.

Why it matters — The inducement grants signal the company's hiring of new employees and standard equity-based compensation practices, which ZVRA watchers would track as part of routine corporate governance disclosures.

Zevra Therapeutics Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

Zevra Therapeutics reported second-quarter 2026 net revenue of $39.7 million, up 53% from $25.9 million a year earlier, driven primarily by U.S. sales of its Niemann-Pick disease type C treatment MIPLYFFA.

Why it matters — The substantial year-over-year revenue increase, led by MIPLYFFA sales, signals growing commercial traction for Zevra's key treatment.

Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Zevra Therapeutics held its Q2 2026 earnings call, and Seeking Alpha published the full transcript of the event. The transcript covers the company's quarterly results and management discussion as presented during the call.

Why it matters — ZVRA watchers can review the transcript for management commentary and details on the company's second-quarter 2026 performance directly from the call.

FAQ

Frequently asked questions about ZVRA stock

What is the ZVRA stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Zevra Therapeutics, Inc. have a median 12-month price target of $24, with estimates ranging from $20 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZVRA stock a buy right now?

Of the 9 analysts covering Zevra Therapeutics, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zevra Therapeutics, Inc. 98 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZVRA?

As at 10 Sept 2026, Zevra Therapeutics, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will ZVRA stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +99.8% from the last close, and Ticker Nerd's factor model ranks Zevra Therapeutics, Inc. 98 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZVRA stock forecast for 2030?

No analyst covering Zevra Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZVRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $35 over the next 12 months.

How has ZVRA stock performed over the past year?

Zevra Therapeutics, Inc. returned +51.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zevra Therapeutics, Inc. do?

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on rare diseases.

What is the latest news on ZVRA?

The most recent item we track (GlobeNewsWire, 2 Sept 2026): "Zevra Therapeutics to Present at Upcoming Investor Conferences". Zevra Therapeutics announced that members of its executive leadership team will present at upcoming investor conferences in New York, NY. The company is a commercial-stage firm focused on therapeutics for people living with rare diseases.

Company

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on rare diseases. Its current business centers on developing and commercializing therapies for patients with serious conditions that have limited or no treatment options, with approved products and late-stage assets spanning Niemann-Pick disease type C, urea cycle disorders, and related neurological and metabolic disorders. The company’s portfolio includes marketed medicines, active clinical programs, and partnership-derived royalty interests, reflecting a model that combines direct product commercialization with pipeline development. Zevra Therapeutics also uses its Ligand Activated Technology platform to support product development. Headquartered in the United States, Zevra Therapeutics plays a focused role in the rare disease market by advancing specialized treatments for patient populations with significant unmet medical needs.

CEO Mr. Neil F. McFarlane · 61 employees · United States · https://www.zevra.com